Copyright
©The Author(s) 2020.
World J Gastroenterol. May 21, 2020; 26(19): 2349-2373
Published online May 21, 2020. doi: 10.3748/wjg.v26.i19.2349
Published online May 21, 2020. doi: 10.3748/wjg.v26.i19.2349
Figure 5 MiR-301a directly targets TP63 in pancreatic cancer.
A: Prediction of miR-301a binding to the 3’ untranslated region (3’UTR) of TTP; B: Luciferase reporter assays confirmed that P63 was a miR-301a target gene; C: Immunofluorescence was performed to detect the expression of P63 in miR-301a-upregulated cell lines under normoxia and hypoxia; D and E: Western blot was performed to detect the expression of P63 protein after the overexpression and knockout of miR-301a; G: The expression of TP63 and the epithelial-mesenchymal transition markers were detected in the miR-301a-upregulated BxPC-3 cell line by Western blot, and (F) Transwell assays were performed to measure cell migration; H: TP63 was knocked down in the miR-301a knockout cell line PANC-1, and (F) Transwell assays were performed to measure cell migration. bP < 0.01, cP < 0.001.
- Citation: Zhang KD, Hu B, Cen G, Yang YH, Chen WW, Guo ZY, Wang XF, Zhao Q, Qiu ZJ. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer. World J Gastroenterol 2020; 26(19): 2349-2373
- URL: https://www.wjgnet.com/1007-9327/full/v26/i19/2349.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i19.2349